{"id":"kw-6500","safety":{"commonSideEffects":[{"rate":null,"effect":"Increased appetite"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hyperglycemia"}]},"_chembl":{"chemblId":"CHEMBL4300557","moleculeType":"Small molecule","molecularWeight":"574.67"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"KW-6500 acts as a ghrelin receptor (GHS-R1a) agonist, mimicking the action of endogenous ghrelin to stimulate pituitary growth hormone secretion. This mechanism aims to increase circulating growth hormone levels in patients with growth hormone deficiency or related conditions. The long-acting formulation allows for less frequent dosing compared to shorter-acting growth hormone secretagogues.","oneSentence":"KW-6500 is a long-acting growth hormone secretagogue that stimulates growth hormone release by activating ghrelin receptors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:57.799Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Growth hormone deficiency in adults"}]},"trialDetails":[{"nctId":"NCT00610103","phase":"PHASE2","title":"Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa Therapy","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2007-11","conditions":"Parkinson's Disease","enrollment":16},{"nctId":"NCT00955318","phase":"PHASE3","title":"Long-Term Safety Study of KW-6500 in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2009-07","conditions":"Parkinson's Disease","enrollment":58},{"nctId":"NCT01063621","phase":"PHASE3","title":"Extended Long-Term Safety Study of KW-6500","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2010-01","conditions":"Parkinson's Disease","enrollment":27},{"nctId":"NCT01058291","phase":"PHASE3","title":"Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2010-01","conditions":"Parkinson's Disease","enrollment":31}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Apomorphine hydroshloride (USAN)"],"phase":"phase_3","status":"active","brandName":"KW-6500","genericName":"KW-6500","companyName":"Kyowa Kirin Co., Ltd.","companyId":"kyowa-kirin-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KW-6500 is a long-acting growth hormone secretagogue that stimulates growth hormone release by activating ghrelin receptors. Used for Growth hormone deficiency in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}